The summer doldrums are over, and the IPO market is ready to return in a big way, with eight deals planned for this week.
I’ve already written a post highlighting half of them — Volaris, Benefitfocus, Fate Therapeutics and Five Prime Therapeutics. Now, we’ll take a look at the remaining four: Acceleron Pharma, Bind Therapeutics, FireEye and Rocket Fuel.
Aceceleron Pharma is a clinical-stage biotech company focused on novel protein therapeutics that target cancer and rare diseases. The approach is about unlocking the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily. Basically, this is a group of molecules that are regulators in the growth and repair of tissues. So far, the company has three proteins in 12 ongoing Phase 2 clinical trials.
To help the process along, Acceleron has forged a worldwide collaboration agreement with Celgene (CELG) — a deal that could result in up to $567 million in milestone payments.
Acceleron plans to issue 4.7 million shares on the Nasdaq under the ticker “XLRN” at a range of $13 to $15. Lead underwriters are Citigroup (C) and Leerink Swann.
Bind Therapeutics is another clinical-stage biotech company. However, BIND’s focus has been on the development of a nanomedicine platform that targets specific cells or tissues using physical and chemical characteristics.
The lead candidate, called BIND-014, currently is going through Phase 2 trials to test it as a treatment of non-small-cell lung cancer. As a sign of its strength, Bind has snagged collaboration deals with major pharma outfits including Amgen (AMGN), Pfizer (PFE) and AstraZeneca (AZN). If all the milestones are hit, the company could reap over $1 billion, including $450 million in pre-commercial milestones.
Bind Therapeutics plans to issue 4.7 million shares on the Nasdaq under the ticker “BIND” at a range of $14 to $16. Lead underwriters are Credit Suisse (CS) and Cowen & Company.
FireEye is a top player in the online security market. The founder of the company, Ashar Aziz, saw a big opportunity to build systems to attack the problems of emerging technologies like social networking, cloud computing, mobile devices and virtualization. It also boasts a top-notch CEO, David DeWalt, who previously helmed McAfee and sold it for $7.7 billion to Intel (INTC) in 2011.
For the most part, FireEye works in real-time and uses sophisticated algorithms to spot potential security issues in the early stages. And this is done with little disruption to a company’s network.
FireEye has been a fast grower, with revenues jumping from $11.8 million in 2010 to $83.3 million in 2012, though losses also climbed from $9.5 million to $35.8 million during this same time.
FireEye intends to issue 14 million shares on the Nasdaq under the ticker “FEYE” at a range of $12 to $14. Lead underwriters include Morgan Stanley (MS), Goldman Sachs (GS), JPMorgan (JPM) and Barclays (BCS).
Rocket Fuel operates an ad network that leverages big data and artificial intelligence. The system optimizes campaigns based on brand awareness, lower acquisition costs and improved sales conversions rates.
The customer base includes 65 of the Advertising Age 100 leading national advertisers and 40 of the Fortune 100 companies, and from 2010 to 2012, revenues surged from $16.5 million to $106.6 million. However, the company still has suffered losses in every year of its existence.
Rocket Fuel plans to issue 4 million shares on the Nasdaq under the ticker “FUEL” at a range of $24 to $27. Lead underwriters include Credit Suisse and Citigroup.
Tom Taulli runs the InvestorPlace blog IPO Playbook. He is also the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.